PCV

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

Retrieved on: 
Thursday, February 17, 2022
Webcast, ID, Company, Infection, Vaccine, SAN, PCV, Antigen, Sutro Biopharma, Genetically modified bacteria, Investor, Periodontal disease, GLOBE

SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022.

Key Points: 
  • SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022.
  • ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
  • Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Retrieved on: 
Monday, February 14, 2022
ASX, Bascom Palmer Eye Institute, Patient, DME, Senior Consultant, CEO, ID, Head, Visual acuity, Diabetic retinopathy, Company, FAMS, Database, Combination, SEC, Royal College of Ophthalmologists, PCV, Nasdaq, Safety, GLOBE, Technology, Intravitreal injection, Treatment, COAST, AMD, Population, Shore, Patent, Private Securities Litigation Reform Act, Overalls, VEGF, Research, Retina, Investment, Bascom, MCI, Program, Ranibizumab, Conference, Industry, Drug development, Pharmaceutical industry

MELBOURNE, Australia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,” was held virtually on Saturday, February 12, 2022, and appeared in a session highlighting “Emerging and Current Therapies for Exudative AMD.” Professor Gemmy Cheung MBBS, FRCOphth, FAMS, MCI, Head and Senior Consultant, Medical Retina Department, Singapore National Eye Center, Singapore Eye Research Institute, Singapore, presented.

Key Points: 
  • The presentation, entitled OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy, was held virtually on Saturday, February 12, 2022, and appeared in a session highlighting Emerging and Current Therapies for Exudative AMD.
  • Polypoidal Choroidal Vasculopathy (PCV) is a subtype of AMD that is particularly prevalent among Asian populations and demonstrates variable response to anti-VEGF-A therapy.
  • Sixty-six participants (18%) with PCV out of a total study population of 366 were included in the analysis.
  • We look forward to continuing to partner with Opthea to investigate the safety and efficacy of OPT-302 combination therapy targeting PCV.

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 10, 2022
GLOBE, Genetically modified bacteria, PCV, Conference, Investor, Company, Periodontal disease, Antigen, Infection, Vaccine, Webcast, Sutro Biopharma, SAN

SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m.

Key Points: 
  • SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m.
  • A live webcast of the presentation can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .
  • Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

Retrieved on: 
Wednesday, February 9, 2022
NASDAQ, Ranibizumab, Diabetic retinopathy, GLOBE, ASX, Patent, PCV, Research, Investment, Technology, Patient, Retina, Safety, Overalls, VEGF, DME, CEO, Drug development, AMD, Pharmaceutical industry

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022.

Key Points: 
  • MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022.
  • There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage.
  • Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities.
  • Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises.

Wet Age-Related Macular Degeneration Disease Market Analysis Report 2021: Bevacizumab's Price Allows it to Remain a Primary Option for Wet AMD - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Health, Pharmaceutical, Growth, Eye, Patient, Ranibizumab, RAP, Roche, VEGF, PCV, HAWK, Patent, Visual acuity, Cancer, Disease, Injection, Severe cognitive impairment, Ageing, Time, FDA, Novartis, AMD, Regeneron Pharmaceuticals, Pharmaceutical industry, Bevacizumab

The "Disease Analysis: Wet Age-Related Macular Degeneration" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Wet Age-Related Macular Degeneration" report has been added to ResearchAndMarkets.com's offering.
  • Age-related macular degeneration (AMD) is the progressive degradation of the part of the eye responsible for visual acuity, causing a loss of central vision.
  • Even with Roche's efforts to position Lucentis ahead of Avastin, and the introduction of Eylea into the market, bevacizumab's low price continues to merit its off-label use in wet AMD.
  • Despite the availability of anti-VEGF medicines that have revolutionized the treatment of wet AMD, pressing unmet needs remain.

BLOCKCHANCE2021: Blockchain leaves the hype behind

Retrieved on: 
Tuesday, January 25, 2022
Ethereum, Cross, Daos, Compound, Laas, CEO, Decentralized finance, Student, Solution, Financial management, Blockchain, NFT, AAVE, Liquidity, Solana, Non-fungible token, PCV, Cryptocurrency, EU

Decentralized technologies such as blockchain can be used to preserve liberal democracies rather than clashing with current systems.

Key Points: 
  • Decentralized technologies such as blockchain can be used to preserve liberal democracies rather than clashing with current systems.
  • This is a move towards a more rationally based model of how blockchain can serve different sectors.
  • "For blockchain to arrive in the mainstream public, we need to educate them how blockchain can shape a positive and sustainable future," explains Fabian Friedrich, CEO and Founder BLOCKCHANCE.
  • As a founding member of the EU interest group Inatba, BLOCKCHANCE is considered an accelerator hub in the blockchain community.

BLOCKCHANCE2021: Blockchain leaves the hype behind

Retrieved on: 
Tuesday, January 25, 2022
Ethereum, Cross, Daos, Compound, Laas, CEO, Decentralized finance, Student, Solution, Financial management, Blockchain, NFT, AAVE, Liquidity, Solana, Non-fungible token, PCV, Cryptocurrency, EU

Decentralized technologies such as blockchain can be used to preserve liberal democracies rather than clashing with current systems.

Key Points: 
  • Decentralized technologies such as blockchain can be used to preserve liberal democracies rather than clashing with current systems.
  • This is a move towards a more rationally based model of how blockchain can serve different sectors.
  • "For blockchain to arrive in the mainstream public, we need to educate them how blockchain can shape a positive and sustainable future," explains Fabian Friedrich, CEO and Founder BLOCKCHANCE.
  • As a founding member of the EU interest group Inatba, BLOCKCHANCE is considered an accelerator hub in the blockchain community.

Vaxcyte Announces Pricing of $100 Million Public Offering

Retrieved on: 
Thursday, January 13, 2022
Telephone, Sutro Biopharma, SAN, Antigen, Exercise, 3rd Floor, SEC, Jefferies, Equity capital markets, Infection, BofA Securities, Jefferies Group, Attention, GLOBE, U.S. Securities and Exchange Commission, Madison Avenue, Periodontal disease, Needham & Company, Company, Bank of America, Sale, Australian securities law, Prospectus, Security (finance), PCV, Genetically modified bacteria, Vaccine

Vaxcyte is selling 2,500,000 shares of common stock and pre-funded warrants to purchase 2,500,000 shares of common stock in the offering.

Key Points: 
  • Vaxcyte is selling 2,500,000 shares of common stock and pre-funded warrants to purchase 2,500,000 shares of common stock in the offering.
  • The shares of common stock are being sold at a public offering price of $20.00 per share, and the pre-funded warrants are being sold at a public offering price of $19.999 per underlying share.
  • The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants.
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Wednesday, January 12, 2022
Telephone, Sutro Biopharma, SAN, Antigen, 3rd Floor, SEC, Jefferies, Equity capital markets, Infection, BofA Securities, Jefferies Group, Attention, GLOBE, U.S. Securities and Exchange Commission, Madison Avenue, Periodontal disease, Needham & Company, Company, Bank of America, Sale, Company and Securities Law Journal, Prospectus, Security (finance), PCV, Genetically modified bacteria, Vaccine

All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Key Points: 
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
  • Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants).
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Retrieved on: 
Thursday, January 6, 2022
PD, Meningitis, Subclinical infection, Periodontal disease, Vaccine, Safety, Antigen, Food, Trial of the century, Sutro Biopharma, Streptococcus, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Chemistry, Company, Private Securities Litigation Reform Act, Sinusitis, IND, Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Otitis media, IPD, Investigational New Drug, U.S. Securities and Exchange Commission, Security (finance), Immunodeficiency, SEC, Bacteria, FDA, PCV, Disease, Mortality, SAN, GLOBE, Incidence, Pneumonia, Public health, Genetically modified bacteria, Death, Pharmaceutical industry, COVID-19

SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. Vaxcyte expects to initiate the VAX-24 Phase 1/2 clinical proof-of-concept study in adults in the first quarter of 2022 and announce topline immunogenicity results by the end of the year.

Key Points: 
  • It can result in invasive PD (IPD), including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis.
  • Antibiotics are used to treat pneumococcal disease, but some strains of the bacteria have developed resistance to treatments.
  • The public health community continues to affirm the need for vaccines that offer broader protection to prevent pneumococcal disease.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.